Syros Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€332.56K - Cost of goods sold
€528.13K - Gross profit
-€760.75K - SG&A expenses
€20.05M - R&D expenses
€75.84M - EBITDA
-€78.59M - D&A
€1.09M - EBIT
-€96.08M - Interest expenses
€4.59M - EBT
-€84.27M - Tax expenses
€9.63M - Net income
-€84.27M
Cash flow statement
- Net deferred tax
€6.96M - Non-cash items
-€16.55M - Changes in working capital
€2.91M - Operating cash flow
-€86.17M - Capex
€32.74K - Other investing cash flow
€22.97M - Net investing cash flow
€1.68M - Total cash dividends paid
€0.00 - Issuance of common stock
€37.28M - Debt repayment
€0.00 - Other financing cash flow
-€98.22K - Net financing cash flow
€37.18M - Foreign exchange effects
€833.12K - Net change in cash
-€46.48M - Cash at end of period
€52.03M - Free cash flow
-€86.14M
Balance sheet
- Cash and cash equivalents
€50.21M - Cash and short-term investments
€50.21M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€4.87M - Total current assets
€55.08M - Property, plant & equipment
€15.15M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€3.00M - Total non-current assets
€18.15M - Total assets
€73.23M - Accounts payable
€8.31M - Short-term debt
€2.23M - Other current liabilities
€11.70M - Total current liabilities
€24.46M - Long-term debt
€49.66M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€8.69M - Total non-current liabilities
€58.35M - Total liabilities
€82.81M - Common stock
€23.26K - Retained earnings
-€651.54M - Other equity
€0.00 - Total equity
-€9.58M - Total liabilities and shareholders' equity
€73.23M
Company information
- Market capitalization
€684.32K - Employees
68 - Enterprise Value
€2.73M
Company ratios
- Gross margin
-
-228.8% Much better than peer group: -62,874,635,072,624.5% - EBITDA margin
-
-23,631.1% Much better than peer group: -345,726,881,828,308.8% - EBIT margin
-
-28,892.2% Much better than peer group: -348,954,384,801,291.4% - EBT margin
-
-25,340.7% Much better than peer group: -348,540,288,405,945.2% - Net margin
-
-25,340.7% Much better than peer group: -348,540,288,406,397.8% - ROE
-
879.4% Much better than peer group: -325.9% - ROA
-
-115.1% Much worse than peer group: -49.4% - Asset turnover
-
0.5% Worse than peer group: 10.3% - FCF margin
-
-25,921.5% Much better than peer group: -290,410,355,645,219.2% - FCF yield
-12,597.1% - Efficiency ratio
23,731.1% - Net sales per employee
-
€4.89K - Net income per employee
-
-€1.24M